Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs. Avanafil, from 50 to 200 mg, is effective and well tolerated for the treatment of ED from 50 to 200 mg, and an increase in dosage is associated with a significant rise in effectiveness but not with more adverse events significantly.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 80 mg/mL|
The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis.
Wang H, et al. Curr Med Res Opin. 2014 Apr 14. PMID: 24701971.
|Related PDE Products|
GLPG1690 is a first-in-class autotaxin (ATX) inhibitor, with IC50 of 131 nM and Ki of 15 nM.
RVT-501 (E6005) is a selective phosphodiesterase 4 (PDE4PDE4) inhibitor with an IC50 of 2.8 nM.
Vardenafil Hcl is a PDE5 inhibitor used for treating erectile dysfunction.
Udenafil(DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction.
Theophylline is a methylated xanthine derivative; competitive nonselective phosphodiesterase inhibitor and nonselective adenosine receptor antagonist.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.